© 2018 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Developing a vaccine to prevent HIV infection has been a significant challenge.
A new study suggests that 48 weeks of treatment with Trizivirî is comparable to a protease inhibitor-based regimen.
Early data from a study comparing Lexiva (fosamprenavir) to Reyataz (atazanavir), both combined with low-dose Norvir (ritonavir), suggest that...
While the value of viral load testing is pretty much undisputed with respect to monitoring HIV-positive people while on treatment, a recent st...
Three reports presented Friday at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco have shed...
New follow-up data from a clinical trial evaluating Merck’s experimental integrase inhibitor MK-0518 in HIV-positive people who have tried and...
A growing number of HIV-positive people who have never taken HIV medications appear to have virus mutations that can cause drug resistance to...
The 46th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) opened yesterday in San Francisco with HIV and drug r...
Two companies offering phenotypic drug resistance testing provided new data.
Tibotec Therapeutics has announced the initiation of a clinical trial evaluating different responses to HIV treatment among women and men. The...
One of the most intriguing compounds to be studied as an HIV therapy is mifepristone, a controversial medication sold in the United States as...
New data suggest that MK-0518 does not cause increased cholesterol or triglyceride as a side effect of treatment. The “late breaker” report, h...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
